Cureus
Cure8 research brief
Why This Matters
Pouch surgery is a key restorative option for people with ulcerative colitis, but pouchitis, chronic antibiotic-refractory pouchitis (CARP), pouch failure, and occasional reclassification to Crohn’s disease can cause significant morbidity and require biologic therapy or further surgery.
This study provides real-world pouch outcomes from a Mexican tertiary center over a median 6.2-year follow-up.
Who Should Pay Attention
Patients with ulcerative colitis who have or are considering ileal pouch-anal anastomosis, surgeons and gastroenterologists who manage pouches, and researchers studying pouch complications.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This single-center retrospective study from a tertiary Mexican hospital reviewed 14 ulcerative colitis patients who underwent restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) between 2010 and 2022. Most pouches were J-pouches; median follow-up was 6.2 years.
Pouch-related complications included pouchitis (28.6%), all of which were chronic antibiotic-refractory pouchitis (CARP) and treated with vedolizumab, one pouch failure requiring reconstruction, and one diagnostic reclassification to Crohn’s disease treated with ustekinumab.
The report emphasizes that pouch complications can require escalation to advanced biologics and occasional reoperation. The authors conclude successful pouch outcomes rely on individualized surveillance, multidisciplinary care, and access to biologic therapy during follow-up.
Keep In Mind
Small sample size (14 patients) and single-center, retrospective design limit generalizability. The content here is based on the article abstract; Cure8 did not review full study data beyond the provided text.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCureus
AuthorsPérez Queb AG, Philippe Ponce M, Contreras Avilés E +4 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJun 15, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
Clinical indications and outcomes of pediatric gastrointestinal endoscopy in a resource-limited healthcare system: Findings from the first multicenter study
Endoscopy in this pediatric multicenter series found a high diagnostic yield and confirmed IBD and other treatable conditions; this matters for families and clinicians in resource-limited settings because improving...
IBD colorectal guidelines
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...